-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Author Index: Q

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Qiu, L.
350 - PHF19 Inhibits Multiple Myeloma Cell Response to Immunotherapy Via Promoting Immunosuppressive Microenvironment
1559 - Zanubrutinib Plus Ixazomib and Dexamethasone for Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Prospective, Phase II Study
1585 - A First-in-Human Phase I Dose Escalation Study of IMM01, Sirpα Fc Protein in Patients with Relapsed or Refractory Lymphoma
1906 - The Impact of Dynamic Assessment of Risk Stratification at the Time of Disease Progression in Patients with Multiple Myeloma
2009 - CNCT19 CAR T-Cell Therapy in Relapsed or Refractory B-Cell Lymphoma: Long-Term Results of a Pilot Prospective Clinical Study
2898 - R-DA-Edoch/R-DHAP Alteration Could Overcome High Risk Factors in Younger Mantle Cell Lymphoma
3161 - Multiple Myeloma-Derived Mir-27b-3p Facilitates Tumor Progression Via Promoting Tumor Cell Proliferation and Immunosuppressive Microenvironment
3197 - Genetically Undetectable and Negative Minimal Residual Disease after Induction Therapy Are Equally Crucial for Survival in Multiple Myeloma
3229 - Is the Second Revision of the International Staging System (R2-ISS) for Multiple Myeloma Valid in a Real-World Population from China?
3311 - Updated Results of Fumanba-1: A Phase 1b/2 Study of a Novel Fully Human B-Cell Maturation Antigen-Specific CAR T Cells (CT103A) in Patients with Relapsed and/or Refractory Multiple Myeloma
3327 - Long-Term Activity of Combining CNCT19 with HDT/ASCT in Refractory Large B-Cell Lymphoma: Two-Year Follow-up of a Prospective Phase 1/2 Clinical Trial
4184 - Oligosecretory Waldenström Macroglobulinemia Patients Exhibit Excellent Treatment Response and Outcomes
4212 - An Open-Label, Multicenter,Single-Arm, Phase I Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of XNW5004 in Patients with Relapsed or Refractory Hematologic Malignancies
4482 - Immune Profiling of MM Microenvironment at Single-Cell Resolution
4498 - Impact of Neoplastic Plasma Cells in the Stem Cell Collection on Multiple Myeloma Patients Receiving Autologous Stem Cell Transplantation
4749 - A Retrospective, Matched Paired Analysis Comparing GBM/GBC Versus BEAM/Beac Conditioning Regimen for Autologous Stem Cell Transplantation in Non-Hodgkin’s Lymphoma
LBA-6 - Zanubrutinib Demonstrates Superior Progression-Free Survival (PFS) Compared with Ibrutinib for Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (R/R CLL/SLL): Results from Final Analysis of ALPINE Randomized Phase 3 Study
Quach, H.
160 - Teclistamab in Combination with Subcutaneous Daratumumab and Lenalidomide in Patients with Multiple Myeloma: Results from One Cohort of MajesTEC-2, a Phase1b, Multicohort Study
568 - Mezigdomide (CC-92480), a Potent, Novel Cereblon E3 Ligase Modulator (CELMoD), Combined with Dexamethasone (DEX) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Preliminary Results from the Dose-Expansion Phase of the CC-92480-MM-001 Trial
1857 - Carfilzomib Use Among Patients with Relapsed/Refractory Multiple Myeloma in the Asia Pacific Region: Characteristics and Outcomes By Regimen from a Prospective, Real-World Study
1923 - Subcutaneous Isatuximab Administration By an on-Body Delivery System (OBDS) in Combination with Pomalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Phase 1b Expansion Study Results
3176 - Isatuximab Plus Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma: Ikema Subgroup Analysis By Number of Prior Lines of Treatment
3232 - An Updated Safety and Efficacy Analysis of Venetoclax Plus Daratumumab and Dexamethasone in an Expansion Cohort of a Phase 1/2 Study of Patients with t(11;14) Relapsed/Refractory Multiple Myeloma
3235 - Preliminary Safety of a Bcl-2 Inhibitor, Bgb-11417, in Patients with Relapsed/Refractory Multiple Myeloma Harboring t(11,14): A Non-Randomized, Open-Label, Phase 1b/2 Study
3245 - Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Transplant-Ineligible Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM): Clinical Assessment of Key Subgroups of the Phase 3 Maia Study
3253 - Isatuximab in Combination with Lenalidomide and Dexamethasone in Patients with High-Risk Smoldering Multiple Myeloma: Updated Safety Run-in Results from the Randomized Phase 3 Ithaca Study
4460 - Circulating RAS/RAF and DNA-Repair Gene Mutations Associates with High-Risk/Treatment Resistance in Primary Refractory Multiple Myeloma
4553 - Daratumumab Plus Lenalidomide and Dexamethasone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Maia Age Subgroup Analysis
4559 - Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of the Phase 3 Maia Study
4568 - Secondary Analysis of the MM21 Trial: Response Adaptive Salvage Treatment with Daratumumab-Lenalidomide-Dexamethasone (DRd) for Newly Diagnosed Transplant Eligible Multiple Myeloma Patients Failing Front-Line Bortezomib-Based Induction Therapy
4571 - A Phase 1/2, First-in-Human, Multicenter, Open-Label, Dose Escalation and Dose-Expansion Study of Single-Agent ISB 1442 in Patients with Relapsed/Refractory Multiple Myeloma
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z